# Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

> **NCT05481476** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 32 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Sintilimab
- **DRUG:** AG

## Key facts

- **NCT ID:** NCT05481476
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481476, "Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05481476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*